Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Theralase Technologies

Drug Profile

Coronavirus vaccine - Theralase Technologies

Alternative Names: Photo Dynamic Compound Inactivated SARS-CoV-2 Vaccine - Theralase Technologies

Latest Information Update: 16 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theralase Technologies; University of Manitoba
  • Developer Public Health Agency of Canada; Theralase Technologies; University of Manitoba
  • Class COVID-19 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 29 Apr 2022 Theralase plans a preclinical trial for COVID-2019 infections in 2Q 2022
  • 09 Apr 2021 Theralase Technologies executes a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health Agency of Canada (PHAC) for the research and development of a Canadian-based SARS-CoV-2 (COVID-19) vaccine
  • 09 Apr 2021 Early research in COVID-2019 infections (Prevention) in Canada, prior to April 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top